Loading…
This entity appears on both sides of lobbying disclosures. The firm tab shows registrant-reported income; the client tab shows client-reported lobbying spend. Contract awards are separate and are not included here.
Lobbying Spend
$185K
Filings
81
Firms Hired
2
Active Period
1999–2026
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Living Organ Donor Tax Credit Act
2026 · third_quarter · Firm: CURA STRATEGIES
Policies to relating to organ donation (H.R. 4583/4582 & S. 1552, the Living Donor Protection Act; H.R. 3698, the Living Organ Donor Tax Credit Act) and research into polycystic kidney disease (H.R. 9169, the PKD Cures Act).
Client expense: — · Firm income: $10,000
Matched citations: H.R. 3698
Living Donor Protection Act of 2025
2026 · third_quarter · Firm: CURA STRATEGIES
Policies to relating to organ donation (H.R. 4583/4582 & S. 1552, the Living Donor Protection Act; H.R. 3698, the Living Organ Donor Tax Credit Act) and research into polycystic kidney disease (H.R. 9169, the PKD Cures Act).
Client expense: — · Firm income: $10,000
Matched citations: H.R. 4583
Policies to relating to organ donation (H.R. 4583/4582 & S. 1552, the Living Donor Protection Act; H.R. 3698, the Living Organ Donor Tax Credit Act) and research into polycystic kidney disease (H.R. 9169, the PKD Cures Act).
Client expense: — · Firm income: $10,000
Matched citations: H.R. 9169
Living Donor Protection Act of 2025
2026 · third_quarter · Firm: CURA STRATEGIES
Policies to relating to organ donation (H.R. 4583/4582 & S. 1552, the Living Donor Protection Act; H.R. 3698, the Living Organ Donor Tax Credit Act) and research into polycystic kidney disease (H.R. 9169, the PKD Cures Act).
Client expense: — · Firm income: $10,000
Matched citations: S. 1552
Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2011
2011 · third_quarter · Firm: PKD FOUNDATION
Comprehensive Immunosupressive Drug Coverage for Kidney Transplant Patients Act (HR 2969/S 1454) sought to increase co-sponsors
Client expense: $15,000 · Firm income: —
Matched citations: HR 2969
Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2009
2010 · fourth_quarter · Firm: PKD FOUNDATION
Seeking co-sponsorship for and passage of the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act (HR 1458/S 565)
Client expense: $20,000 · Firm income: —
Matched citations: HR 1458
Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2009
2010 · fourth_quarter · Firm: PKD FOUNDATION
Seeking co-sponsorship for and passage of the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act (HR 1458/S 565)
Client expense: $20,000 · Firm income: —
Matched citations: S 565
Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2009
2010 · fourth_quarter · Firm: PKD FOUNDATION
Seeking co-sponsorship for and passage of the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act (HR 1458/S 565)
Client expense: $20,000 · Firm income: —
Matched citations: HR 1458
Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2009
2010 · fourth_quarter · Firm: PKD FOUNDATION
Seeking co-sponsorship for and passage of the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act (HR 1458/S 565)
Client expense: $20,000 · Firm income: —
Matched citations: S 565
Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2009
2010 · second_quarter · Firm: PKD FOUNDATION
H.R. 1458/S. 565 Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act: Met with Ways and Means committee staff; advocacy to increase co-sponsorship of the bill
Client expense: $30,000 · Firm income: —
Matched citations: H.R. 1458
Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2009
2010 · second_quarter · Firm: PKD FOUNDATION
H.R. 1458/S. 565 Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act: Met with Ways and Means committee staff; advocacy to increase co-sponsorship of the bill
Client expense: $30,000 · Firm income: —
Matched citations: S. 565
Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2009
2010 · first_quarter · Firm: PKD FOUNDATION
Ask for co-sponsorship and support for the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act (HR 1458/S 565)
Client expense: $40,000 · Firm income: —
Matched citations: HR 1458
Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2009
2010 · first_quarter · Firm: PKD FOUNDATION
Ask for co-sponsorship and support for the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act (HR 1458/S 565)
Client expense: $40,000 · Firm income: —
Matched citations: S 565
Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2009
2009 · fourth_quarter · Firm: PKD FOUNDATION
Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Act (HR 1458/S. 565)
Client expense: $10,000 · Firm income: —
Matched citations: HR 1458
Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2009
2009 · fourth_quarter · Firm: PKD FOUNDATION
Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Act (HR 1458/S. 565)
Client expense: $10,000 · Firm income: —
Matched citations: S. 565
Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2009
2009 · fourth_quarter · Firm: PKD FOUNDATION
NIH/NIDDK funding for PKD research and report language with in the FY 2010 Labor-Health and Human Services- Education Appropriations bill; PKD research within the Peer Reviewed Medical Reserach Program(PRMRP) and the Congressionally Directed Medical Research Programs (CDMRP) in the FY 2010 Defense Appropriations bill; Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act (HR 1458/S 565)
Client expense: — · Firm income: —
Matched citations: HR 1458
Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2009
2009 · fourth_quarter · Firm: PKD FOUNDATION
NIH/NIDDK funding for PKD research and report language with in the FY 2010 Labor-Health and Human Services- Education Appropriations bill; PKD research within the Peer Reviewed Medical Reserach Program(PRMRP) and the Congressionally Directed Medical Research Programs (CDMRP) in the FY 2010 Defense Appropriations bill; Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act (HR 1458/S 565)
Client expense: — · Firm income: —
Matched citations: HR 1458
Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2009
2009 · fourth_quarter · Firm: PKD FOUNDATION
NIH/NIDDK funding for PKD research and report language with in the FY 2010 Labor-Health and Human Services- Education Appropriations bill; PKD research within the Peer Reviewed Medical Reserach Program(PRMRP) and the Congressionally Directed Medical Research Programs (CDMRP) in the FY 2010 Defense Appropriations bill; Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act (HR 1458/S 565)
Client expense: — · Firm income: —
Matched citations: HR 1458
Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2009
2009 · fourth_quarter · Firm: PKD FOUNDATION
NIH/NIDDK funding for PKD research and report language with in the FY 2010 Labor-Health and Human Services- Education Appropriations bill; PKD research within the Peer Reviewed Medical Reserach Program(PRMRP) and the Congressionally Directed Medical Research Programs (CDMRP) in the FY 2010 Defense Appropriations bill; Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act (HR 1458/S 565)
Client expense: — · Firm income: —
Matched citations: S 565
Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2009
2009 · fourth_quarter · Firm: PKD FOUNDATION
NIH/NIDDK funding for PKD research and report language with in the FY 2010 Labor-Health and Human Services- Education Appropriations bill; PKD research within the Peer Reviewed Medical Reserach Program(PRMRP) and the Congressionally Directed Medical Research Programs (CDMRP) in the FY 2010 Defense Appropriations bill; Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act (HR 1458/S 565)
Client expense: — · Firm income: —
Matched citations: S 565
Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2009
2009 · fourth_quarter · Firm: PKD FOUNDATION
NIH/NIDDK funding for PKD research and report language with in the FY 2010 Labor-Health and Human Services- Education Appropriations bill; PKD research within the Peer Reviewed Medical Reserach Program(PRMRP) and the Congressionally Directed Medical Research Programs (CDMRP) in the FY 2010 Defense Appropriations bill; Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act (HR 1458/S 565)
Client expense: — · Firm income: —
Matched citations: S 565
American Middle Class Tax (AMT) Relief Act of 2007
2009 · fourth_quarter · Firm: RUSSELL MUELLER
Obtain extension of immunosuppressive drug provisions under federal health programs via hte Senate version of health reform legislation, H.R. 3590, the Patient Protection and Affordable Care Act.
Client expense: — · Firm income: $10,000
Matched citations: H.R. 3590
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2010
2009 · fourth_quarter · Firm: RUSSELL MUELLER
Obtained mention of PKD in Senate FY2010 Defense appropriations bill for research and clinical funding under Defense Peer Reviewed Medical Research Program (Senate version of H.R. 3326); Obtained report language for PKD forum and clinical treatment centers under FY2010 HHS/NIH/NIDDK appropriations House and Senate bills, H.R. 3293, as passed as part of Consolidated Appropriations Act, H.R. 3288, and obtained funding for PKD education efforts under H.R. 3293 and H.R 3288.
Client expense: — · Firm income: $10,000
Matched citations: H.R. 3293
Early Treatment for HIV Act of 2007
2009 · third_quarter · Firm: RUSSELL MUELLER
Obtained mention of PKD in Senate FY 2010 Defense Appropriations bill for research and clinical funding for PKD under Peer Reviewed Medical Research Program (Senate version of H.R. 3326), but did not obtain such funding in the House bill (H.R. 3326); Obtained sponsorship of National PKD Awareness Week Resolution for 2009 (S. Res. 241); Obtained PKD report language under FY 2010 HHS/NIH/NIDDK Appropriations House and Senate versions of H.R. 3293 for PKD forum and clinical treatment centers; Obtained funding under FY 2010 HHS Appropriations for PKD education efforts under House version of H.R. 3293. Medicare legislation: Obtain extension of immunosuppressive drug coverage under federal health programs (S. 565; H.R. 1458 and H.R. 3200).
Client expense: — · Firm income: $10,000
Matched citations: H.R. 3326
Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2009
2009 · third_quarter · Firm: RUSSELL MUELLER
Obtained mention of PKD in Senate FY 2010 Defense Appropriations bill for research and clinical funding for PKD under Peer Reviewed Medical Research Program (Senate version of H.R. 3326), but did not obtain such funding in the House bill (H.R. 3326); Obtained sponsorship of National PKD Awareness Week Resolution for 2009 (S. Res. 241); Obtained PKD report language under FY 2010 HHS/NIH/NIDDK Appropriations House and Senate versions of H.R. 3293 for PKD forum and clinical treatment centers; Obtained funding under FY 2010 HHS Appropriations for PKD education efforts under House version of H.R. 3293. Medicare legislation: Obtain extension of immunosuppressive drug coverage under federal health programs (S. 565; H.R. 1458 and H.R. 3200).
Client expense: — · Firm income: $10,000
Matched citations: H.R. 1458
Source: Senate LDA